SEARCH

SEARCH BY CITATION

References

  • 1
    Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation. Lancet 1982; 2: 12469.
  • 2
    Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 17.
  • 3
    Pouplard C, May MA, Regina S, Marchand M, Fusciardi J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol 2005; 128: 83741.
  • 4
    Girolami B, Prandoni P, Stefani PM, Tanduo C, Sabbion P, Eichler P, Ramon R, Baggio G, Fabris F, Girolami A. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003; 101: 29559.
  • 5
    Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: WarkentinTE, GreinacherA, eds. Heparin-induced Thrombocytopenia, 3rd edn. New York: Marcel Dekker, 2004: 10748.
  • 6
    Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2001; 113: 88690.
  • 7
    Suh JS, Malik MI, Aster RH, Visentin GP. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol 1997; 54: 196201.
  • 8
    Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004; 2: 213337.
  • 9
    Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 5027.
  • 10
    Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999; 106: 62935.
  • 11
    Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG, ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 183843.
  • 12
    Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 2004; 104: 30727.
  • 13
    Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003; 2: 14857.
  • 14
    Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: WarkentinTE, GreinacherA, eds. Heparin-induced Thrombocytopenia, 3rd edn. New York: Marcel Dekker, Inc., 2004: 53106.
  • 15
    Greinacher A, Amiral J, Dummel V, Vissac A, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994; 34: 3815.
  • 16
    Pouplard C, Amiral J, Borg JY, Vissac AM, Delahousse B, Gruel Y. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium. Br J Haematol 1997; 99: 27380.
  • 17
    Pouplard C, Amiral J, Borg JY, Laporte-Simitsidis S, Delahousse B, Gruel Y. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999; 111: 7006.
  • 18
    Chong BH, Chong JH. Heparin-induced thrombocytopenia. Expert Rev Cardiovasc Ther 2004; 2: 54759.
  • 19
    Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163: 251824.
  • 20
    Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121: 53555.
  • 21
    Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 128692.
  • 22
    Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson LE, Greinacher A. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002; 122: 3742.
  • 23
    Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 2005; 127: 185761.
  • 24
    Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 2730.
  • 25
    Warkentin TE, Hayward CPM, Smith CA, Kelly PM, Kelton JG. Determinants of platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992; 120: 3719.
  • 26
    Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med 2001; 138: 2231.
  • 27
    Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 13305.
  • 28
    Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005; 127: 35S45S.
  • 29
    Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol 1996; 95: 1617.
  • 30
    Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: WarkentinTE, GreinacherA, eds. Heparin-induced Thrombocytopenia, 3rd edn. New York: Marcel Dekker, 2004: 271311.
  • 31
    Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66: 7346.
  • 32
    Savi P, Chong BH, Greinacher A, Gruel Y, Kelton JG, Warkentin TE, Eichler P, Meuleman D, Petitou M, Herault JP, Cariou R, Herbert JM. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005; 105: 13944.
  • 33
    Eichler P, Budde U, Haas S, Kroll H, Loreth RM, Meyer O, Pachmann U, Potzsch B, Schabel A, Albrecht D, Greinacher A. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost 1999; 81: 62529.
  • 34
    Gruel Y, Pouplard C, Nguyen P, Borg JY, Derlon A, Juhan-Vague I, Regnault V, Samama M for the French Heparin-Induced Thrombocytopenia Study Group. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol 2003; 121: 78692.
  • 35
    Warkentin TE. Pseudo-heparin-induced thrombocytopenia. In: WarkentinTE, GreinacherA, eds. Heparin-Induced Thrombocytopenia, 3rd edn. New York: Marcel Dekker, 2004: 31334.
  • 36
    Lillo-Le Louet A, Boutouyrie P, Alhenc-Gelas M, Le Beller C, Gautier I, Aiach M, Lasne D. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost 2004; 2: 18828.
  • 37
    Baker J, De Loughery TG, Boshkov L. Lack of value of clinical predictors of heparin induced thrombocytopenia (HIT) in complex patients. Blood 2004; 104: 569a.
  • 38
    Warkentin TE, Sheppard JI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96: 17038.
  • 39
    Warkentin TE, Sheppard JI, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for HIT antibodies: how much class do we need? J Lab Clin Med 2005; 146: 3416.